Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections

Journal of Clinical Microbiology

Volumn 50, Issue 8, 2012, Pages 2548-2552

  Holmes, Natasha E ^a,b   Johnson, Paul D R ^a,b,c   Howden, Benjamin P ^a,b,c  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; METICILLIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

AGR GENE; ANTIBIOTIC SENSITIVITY; BACTERIAL CELL WALL; BACTERIUM COLONY; BACTERIUM IDENTIFICATION; CLINICAL FEATURE; DRUG TREATMENT FAILURE; EPSILOMETER TEST; GENE; GENE MUTATION; HUMAN; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VANCOMYCIN HETERORESISTANT STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN RESISTANCE;

STAPHYLOCOCCUS AUREUS;

EID: 84864398588     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00775-12     Document Type: Short Survey

References (34)

1. British Society for Antimicrobial Chemotherapy (BSAC). 2011. BSAC methods for antimicrobial susceptibility testing, version 10.2. British Society for Antimicrobial Chemotherapy, Birmingham, United Kingdom. http://www.bsac.org.uk/ Susceptibility+Testing/Breakpoints.
2. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451. (Pubitemid 38200128)
3. Clinical and Laboratory Standards Institute (CLSI). 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-seventh edition. CLSI document M07-A7. CLSI, Wayne, Philadelphia, PA.
4. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. 2000. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob. Agents Chemother. 44:2276-2285. (Pubitemid 30650868)
5. Elsaghier AA, Aucken HM, Hamilton-Miller JM, Shaw S, Kibbler CC. 2002. Resistance to teicoplanin developing during treatment of methicillin-resistant Staphylococcus aureus infection. J. Antimicrob. Chemother. 49:423-424. (Pubitemid 34162643)
6. European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2011. MIC and inhibition zone diameter distributions of microorganisms without and with resistance mechanisms. EUCAST, Växjö, Sweden. http://www.eucast.org/mic-distributions/.
7. Hiramatsu K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1:147-155. (Pubitemid 33586048)
8. Hiramatsu K, et al. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673. (Pubitemid 28036828)
9. Holland TL, Fowler VG, Jr. 2011. Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet? J. Infect. Dis. 204:329-331.
10. Holmes NE, et al. 2011. Antibiotic choice may not explain poorer outcomes in patients With Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J. Infect. Dis. 204:340-347.
11. Horne KC, et al. 2009. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob. Agents Chemother. 53:3447-3452.
12. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99-139.
13. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK. 2006. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 50:3039-3047. (Pubitemid 44396410)
14. Howden BP, et al. 2011. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog. 7:e1002359. doi:10.1371/journal.ppat.1002359.
15. Howden BP, et al. 2008. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob. Agents Chemother. 52:3755-3762.
16. Howden BP, et al. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528. (Pubitemid 38250962)
17. Hsu DI, et al. 2008. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents 32:378-385.
18. Lodise TP, et al. 2008. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 62:1138-1141.
19. Maor Y, et al. 2009. Clinical features of heteroresistant vancomycinintermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 199:619-624.
20. Marlowe EM, Cohen MD, Hindler JF, Ward KW, Bruckner DA. 2001. Practical strategies for detecting and confirming vancomycinintermediate Staphylococcus aureus: a tertiary-care hospital laboratory's experience. J. Clin. Microbiol. 39:2637-2639. (Pubitemid 32606246)
21. Metzger S, Price CS, Dunne WMJ, Howson D. 2011. Automated 4-hour detection of heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA), poster 083. Abstr. 111th Gen. Meet. Am. Soc. Microbiol., New Orleans, LA. American Society for Microbiology, Washington, DC.
22. Musta AC, et al. 2009. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 47:1640 -1644.
23. Peleg AY, et al. 2009. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J. Infect. Dis. 199:532-536.
24. Prakash V, Lewis JS II, Jorgensen JH. 2008. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob. Agents Chemother. 52:4528. doi:10.1128/AAC.00904-08.
25. Rybak MJ, et al. 2008. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J. Clin. Microbiol. 46:2950-2954.
26. Sakoulas G, et al. 2002. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 46:1492-1502. (Pubitemid 34415333)
27. Sakoulas G, et al. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402. (Pubitemid 38747480)
28. Soriano A, et al. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200. (Pubitemid 351269157)
29. van Hal SJ, Lodise TP, Paterson DL. 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. 54:755-771.
30. van Hal SJ, Paterson DL. 2011. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55:405-410.
31. van Hal SJ, et al. 2011. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J. Clin. Microbiol. 49:1489-1494.
32. Verdier I, et al. 2004. Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II. Antimicrob. Agents Chemother. 48:1024-1027. (Pubitemid 38280360)
33. Wootton M, et al. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403. (Pubitemid 32303403)
34. Yusof A, et al. 2008. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J. Clin. Microbiol. 46:3042-3047.